What Is Intestinal Dysplasia? Causes, Signs, and Treatment

Intestinal dysplasia is a condition in which the cells lining the gastrointestinal tract develop abnormal size, shape, or organization under the microscope, placing them on a spectrum between healthy tissue and cancer. It is not cancer itself, but it is the clearest warning sign that cancer could develop. The condition most often turns up in people with long-standing inflammatory bowel disease or chronic stomach inflammation, and it rarely produces symptoms of its own, which is why routine surveillance matters so much for those at risk.

What Dysplasia Actually Means in the Gut

When pathologists examine a biopsy taken during an endoscopy, they look at the architecture of the tissue and the appearance of individual cells. In healthy intestinal lining, cells are orderly: nuclei sit at the base, a band of cytoplasm fills the middle, and a cap of mucin (the protective slime the gut produces) sits on top. Dysplastic cells lose this polarity. Their nuclei become enlarged, crowded, or randomly positioned, and the normal layered arrangement breaks down. In one study of 88 dysplastic specimens from the stomach, the characteristic “four-line” pattern of organized cell polarity was disrupted in every single case, regardless of the subtype of dysplasia, while the pattern remained intact in all 57 specimens showing only reactive (inflammation-related) changes.

Pathologists grade dysplasia into two tiers. Low-grade dysplasia features elongated nuclei that are mostly still confined to the lower part of each cell, with mild architectural distortion. High-grade dysplasia is more alarming: nuclei are enlarged and rounded, polarity is lost, and glands crowd together into complex, cribriform (sieve-like) patterns.¹ That grading distinction drives the entire treatment conversation: low-grade findings might be watched, while high-grade findings frequently require action.

Where Intestinal Dysplasia Shows Up

The term “intestinal dysplasia” can refer to abnormal cell growth anywhere along the digestive tract, but there are two major clinical contexts where it comes up most often. The first is in the colon of people living with inflammatory bowel disease, particularly ulcerative colitis and Crohn’s disease involving the large bowel. The second is in the stomach, where chronic Helicobacter pylori infection can trigger a chain of tissue changes: normal stomach lining converts to intestinal-type cells (a process called intestinal metaplasia), and those cells can then become dysplastic.

These two settings share a common thread, which is chronic inflammation, but the monitoring strategies and timelines differ. In the colon, surveillance colonoscopy programs typically begin after about eight years of inflammatory bowel disease symptoms.² In the stomach, monitoring centers on people with documented intestinal metaplasia, using upper endoscopy and systematic biopsies. Gastric intestinal metaplasia is usually diagnosed by upper endoscopy with biopsy, and histologic scoring systems help stratify which patients face the highest risk of progressing to cancer.³

Why Chronic Inflammation Is the Central Driver

Chronic inflammation has been identified as a major risk factor for gastrointestinal malignancies, and the molecular and cellular pathways linking the two are increasingly well understood.⁴ When the gut lining is inflamed over years or decades, cells divide more frequently to repair damage. That accelerated turnover increases the chance of DNA copying errors, and over time, some of those errors land in genes that control cell growth. The result is a population of cells that looks and behaves differently from its neighbors.

Genomic profiling of gastric precancerous tissue has identified 26 candidate genes that appear to be under positive selection in intestinal metaplasia. These include well-known cancer-related genes such as KRAS, ARID1A, TP53, and FBXW7. One gene, SOX9, which normally helps regulate intestinal stem cell behavior, was roughly 14 times more likely to carry mutations in metaplastic tissue than in normal stomach lining.⁵ Mutations in TP53, a key tumor-suppressor gene, appear to come later in the sequence. Only about 2% of precancerous stomach samples carried TP53 mutations, compared with roughly half of full-blown gastric cancers, suggesting that TP53 loss tends to occur after dysplasia has already set in.⁶

In the colon, research has shown that the loss of APC (another tumor-suppressor gene) triggers a cascade: it ramps up MYC activity, which in turn degrades the p53 protein. That early loss of p53 function allows hyperproliferation and accumulating DNA damage, eventually enabling further mutations in genes like KRAS that drive aggressive tumor development.⁷ The picture emerging from both stomach and colon research is that dysplasia sits in the middle of a stepwise genetic escalation, with each round of mutation unlocking more abnormal behavior.

Causes and Risk Factors Beyond Inflammation

Long-standing inflammatory bowel disease is the best-recognized risk factor for colorectal dysplasia, and longer disease duration matters. In a matched case-control study, people who developed dysplasia had a median IBD duration of about 12 years, compared with 8 years for those who did not. The study also found that obesity roughly doubled the odds of developing colorectal dysplasia, independent of other factors. And a prior finding of dysplasia was the strongest predictor of future dysplasia, with nearly five times higher odds.⁸

Smoking is another significant contributor. In a large study of precancerous stomach lesions, cigarette smoking nearly doubled the risk of progressing to dysplasia and accounted for almost the entire 55% higher rate of dysplasia observed in men compared with women. A family history of stomach cancer and blood type A were also associated with elevated risk, though more modestly.⁹ Separately, heavy smokers with H. pylori infection who consumed more than 20 cigarettes a day had roughly a four-fold risk of developing intestinal metaplasia, and high butter consumption also increased risk.¹⁰

Dietary factors contribute as well for colorectal polyps that carry dysplastic potential. High red meat intake was strongly associated with sessile serrated polyps, with the highest consumers facing roughly two and a half times the risk. Current smoking raised risk for all polyp types, while regular use of nonsteroidal anti-inflammatory drugs reduced the risk of serrated polyps by about 40%.¹¹

The gut microbiome adds yet another layer. An imbalanced microbial community can promote gastrointestinal malignancy through direct DNA damage to host cells, excessive inflammatory signaling, and activation of tumor-promoting pathways. Organisms including H. pylori, Epstein-Barr virus, certain E. coli strains, and Streptococcus bovis have all been implicated in different gastrointestinal cancers.¹²

Signs and Symptoms, or the Lack of Them

Here is the uncomfortable reality: intestinal dysplasia itself almost never causes symptoms you would notice. There is no characteristic pain, no telltale change in bowel habits, and no bleeding pattern that flags dysplasia specifically. It is a microscopic finding, detected on biopsies taken during endoscopy, not a condition that sends you to the doctor with a complaint.

What you may notice are the symptoms of the underlying disease. People with ulcerative colitis or Crohn’s disease already deal with diarrhea, cramping, blood in the stool, and fatigue. People with chronic gastritis may experience nausea, bloating, or indigestion. None of these symptoms worsen in any predictable way when dysplasia appears. That is precisely why surveillance programs exist: you cannot wait for symptoms to tell you something is wrong.

How Dysplasia Is Found and Confirmed

The standard approach is endoscopy with biopsy. For colorectal surveillance in IBD, guidelines call for systematic sampling of the colon at regular intervals. The question has long been how best to visualize abnormal areas so biopsies can be targeted rather than random. A meta-analysis of endoscopic surveillance methods found that chromoendoscopy, in which dye is sprayed onto the colon lining to highlight subtle surface irregularities, outperforms standard white-light endoscopy. Narrow-band imaging, which uses filtered light to enhance mucosal patterns, performed comparably and took less time.¹³

For stomach surveillance, both traditional forceps biopsies and newer wide-area brushing techniques have been compared. In a multicenter trial, low-grade dysplasia was found in eight patients, and neither biopsy method outperformed the other for detecting it.¹⁴ The takeaway is that vigilance matters more than the specific tool. What counts is that biopsies are taken systematically and read by an experienced pathologist.

Artificial intelligence is beginning to enter this space. A diagnostic test accuracy meta-analysis found that AI algorithms interpreting endoscopic images detected dysplasia with a sensitivity of about 92% and specificity of 84%.¹⁵ These tools are still being refined, but they hold promise as a second pair of eyes during procedures, particularly in settings where expert endoscopists are scarce.

Treatment Depends on the Grade and Setting

There is no pill that reverses dysplasia once it is found. Treatment decisions hinge on whether the dysplasia is low-grade or high-grade, whether it is visible as a defined lesion during endoscopy, and what the underlying disease is. The options span a wide range.

Surveillance for Low-Grade Findings

Low-grade dysplasia in the setting of IBD was not associated with colorectal cancer in a large analysis, while high-grade dysplasia carried a substantially increased cancer risk at the time of colectomy.¹⁶ For many people with low-grade findings, the answer is continued close surveillance: more frequent colonoscopies with targeted biopsies, often every six to twelve months, to watch for any upgrade in the grade or extent of dysplasia.

Endoscopic Removal

When dysplasia appears as a visible, well-defined lesion during endoscopy, endoscopic resection is increasingly used as a first-line approach. A meta-analysis of advanced endoscopic resection for colorectal dysplasia in IBD found a pooled complete-resection rate of about 98%, with low complication rates: perforation occurred in under 1% and bleeding in under 2% of cases. Among patients followed afterward, local recurrence was about 5% and new lesions elsewhere in the colon appeared in roughly 7% over a median follow-up of 33 months. Progression to colorectal cancer during surveillance was rare, occurring in about 0.2% of patients.¹⁷ Non-polypoid (flat) dysplastic lesions can also be resected, though patients with flat lesions tend to have higher rates of subsequent dysplasia and cancer, warranting closer follow-up.¹⁸

Surgery

Colectomy, the surgical removal of part or all of the colon, remains necessary in certain situations. Current gastroenterology guidance recommends surgery when visible dysplasia cannot be fully removed endoscopically, or when biopsy reveals invisible multifocal dysplasia or high-grade dysplasia scattered across the colon lining.¹⁹ The decision is not taken lightly. Losing part or all of the colon changes daily life, and patient surveys reveal that roughly 29% of people who have been through a dysplasia diagnosis felt they were not well informed about the associated cancer risk or their management options. Themes included contradictory advice from different clinicians and a lack of personalized information about how each choice would affect long-term quality of life.²⁰

Chemoprevention and Reducing Your Risk

Because dysplasia in IBD is driven by chronic inflammation, controlling that inflammation is itself a form of prevention. The most studied chemopreventive agent is mesalamine (also known as 5-ASA), a mainstay of ulcerative colitis treatment. Current evidence supports its use in reducing colorectal cancer risk in people with ulcerative colitis. Other drugs, including thiopurines, folic acid, statins, and TNF-alpha inhibitors, have been studied but their chemopreventive benefit remains debated.²

There is cautious optimism in the field. Recent population-based studies have shown that the risk of cancer in IBD may be lower than older hospital-based studies suggested, possibly because of better disease control, wider use of drugs with chemopreventive effects, and the spread of endoscopic surveillance in high-risk patients.²¹ That is good news, but it depends on people actually attending their surveillance appointments and staying on their medications.

Intestinal Neuronal Dysplasia, a Different Condition Entirely

If you search “intestinal dysplasia,” you may also encounter references to intestinal neuronal dysplasia (IND), which despite sharing a name is a fundamentally different condition. IND is not about the lining cells of the gut becoming precancerous. Instead, it involves abnormal development of the nerve cells within the intestinal wall, primarily in young children. The condition mimics Hirschsprung’s disease, a well-known cause of severe constipation in newborns, but has its own set of microscopic features, mainly overgrowth of nerve tissue in the submucosal layer.²²

IND remains controversial among specialists. Unlike Hirschsprung’s disease, where the absence of nerve cells is straightforward to confirm on biopsy, diagnosing IND is plagued by high disagreement among pathologists. A prospective multicentre study found substantial variation in how different pathologists interpreted the same biopsies, casting doubt on the reliability of the diagnosis under previous consensus criteria.²³ Some pediatric gastroenterologists question whether IND is a distinct disease at all, or whether it represents a normal variant that gets overdiagnosed in children with unexplained constipation. If your child has been given this diagnosis, seeking a second opinion from a center with expertise in pediatric motility disorders is reasonable.

Organoid Research and Personalized Medicine

One of the more promising frontiers in understanding and treating intestinal dysplasia comes from organoid technology. Organoids are tiny three-dimensional structures grown from a patient’s own intestinal cells in a lab dish. They retain many of the characteristics of the tissue they came from, including its genetic mutations and its response to specific drugs. Recent research has demonstrated that these patient-derived organoids can serve as a platform for personalized medicine, allowing clinicians to test which treatments a particular patient’s tissue responds to before committing to a therapy.²⁴ While this is still largely a research tool, it represents a shift toward tailoring surveillance and treatment to the individual rather than relying on population-level risk estimates. For a condition where the progression from dysplasia to cancer is unpredictable and varies widely from one person to the next, that kind of precision could eventually change the way the disease is managed.